Results found: 2

Search results

Search:
in the keywords: Polycystic Ovary Syndrome

Sort By:

Limit search:

The quality of life of women suffering from polycystic ovary syndrome

100%

Stadnicka G., Łepecka-Klusek C., Kulesza-Brończyk B., Pilewska-Kozak A.

Progress in Health Sciences

2015

vol. 5

issue 2

61-68

Purpose: To assess how certain clinical symptoms of polycystic ovary syndrome (PCOS) affect the quality of life of women, their activity, and their sexual lives.Materials and methods: The World Health Organization quality of life questionnaire (WHOQOL-Bref) was used to assess the quality of life and health of 78 women diagnosed with PCOS, and the female sexual function questionnaire -28 (FSQ-28) was used to assess their sexual activity and associated disorders.Results: Among three groups of women with varying body mass indexes and aged26.93 years on average, significant differences (p<0.05) were found in quality of life. In individual domains of the WHOQOL-Bref, the median score of women with obesity was lower than that of women with normal body weight or with overweight. Women with symptoms of hirsutism showed lower quality of life than women without these symptoms, while womenwho had undergone treatment for 4–6 years experienced significantly worse quality of life than those who had undergone therapy for less than 3 or more than 6 years. In the various domains of sexual response, regression analysis showed a positive correlation (p <0 .05) between better quality of life and women’s sexual activity.Conclusions: Clinical symptoms of PCOS such as obesity and hirsutism affect women’s quality of life, as does the length of infertility treatment, whereas general quality of life affects the occurrence of disorders in women at particular stages of sexual response.

Hepcydyna w zaburzeniach metabolicznych

63%

Paulina Giemza-Kucharska P., Artur Słomka A., Justyna Kwapisz J., Ewa Żekanowska E.

Medical Review

2012

issue 3

351–355

Hepcydyna jest niewielkim białkiem zaangażowanym w metabolizm żelaza. Poprzez internalizację i degradację ferroportyny, jedynego transportera żelaza z cytoplazmy komórek do krwiobiegu, hepcydyna odpowiedzialna jest za zmniejszenie stężenia tego pierwiastka w surowicy krwi. Wcześniejsze badania dokładnie scharakteryzowały mechanizmy odpowiedzialne za regulację syntezy hepcydyny i jej znaczenie biologiczne. Odkrycie tego białka rzuciło nowe światło na patogenezę takich jednostek chorobowych jak hemochromatoza, niedokrwistość z niedoboru żelaza czy niedokrwistość chorób przewlekłych. Ostatnie badania pokazują, że hepcydyna może pełnić także istotne funkcje w zaburzeniach metabolicznych, takich jak osteoporoza, czy też zespół policystycznych jajników. W niniejszej pracy przedstawiono fijologiczną rolę hepcydyny, jej znaczenie kliniczne oraz potencjalny związek tego białka z remodelingiem kostnym, osteoporozą oraz zespołem policystycznych jajników.

Hepcidin is a small protein involved in iron metabolism. This protein bounds to ferroportin, the sole cellular iron exporter, causing its internalization and degradation, which causes decrease in serum iron concentration. Previous studies have characterized mechanisms of hepcidin synthesis as well as its biological activity. The discovery of hepcidin has shed new light on the pathogenesis of many disease such as hemochromatosis, iron deficiency anemia and anemia of chronic disease. Recent researches have shown, that hepcidin can play vital role in metabolic disorders, such as osteoporosis and polycystic ovary syndrome. The physiological role of hepcidin, its clinical signifiance and potential link with bone remodeling, osteoporosis and polycystic ovary syndrome are described in this review.

Refine search results

1 Medical Review

1 Progress in Health Sciences

1 Artur Słomka A.

1 Ewa Żekanowska E.

1 Justyna Kwapisz J.

1 Kulesza-Brończyk B.

1 Paulina Giemza-Kucharska P.

1 Pilewska-Kozak A.

1 Stadnicka G.

1 Łepecka-Klusek C.

1 2015

1 2012

Search results

The quality of life of women suffering from polycystic ovary syndrome

Hepcydyna w zaburzeniach metabolicznych